The report on Anti-Obesity Prescription Drugs Market by drug class (orlistat, phentermine and topiramate,
bupropion and naltrexone, lorcaserin, liraglutide), distribution channel (retail pharmacy, hospital pharmacy
and online pharmacy), age group (pediatric and adult) trends analysis and forecasts up to 2024 studies the
market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-
Pacific, Rest of the World. According to the report the Global Anti-Obesity Prescription Drugs Market is
projected to grow at a CAGR of 4.97% in terms of value over the period of 2018-2024. The growth in the world
market is primarily driven by significant contribution by North America (Leading region) region to this market.
Get a Sample Request
https://www.infiniumglobalresearch.com/reports/sample_request/1127
Market Insight
The pharmacological agents that helps to reduce or control weight. Anti-obesity drugs help in reducing body
mass either by reducing the hunger or increasing the consumption of calories. The ingesting of unhealthy food
which is rich in cholesterol has increased which leads to a rise in demand for anti-obesity prescription drugs.
Rising level of chronic stress also contributes towards obesity.Rising consumption of alcoholic beverages and
unhealthy food which is rich in cholesterol that leads to obesity is driving the growth of the market. Growing
occurrence of depression has led to growing consumption of the psychotropic drugs; the side effect of this
drug is increasing which result to obesity. Moreover, increasing incidences of diabetes have surged up the
consumption of medications. These medications have appetite stimulating features, due to which the patients
incline to eat more. Eating disorders due to antidepressants and diabetic drugs increase the diet which has
sustained to contribute towards obesity. Growing demand for obesity management is expected to impact
growth of the global anti-obesity prescription drugs market positively.
Infinium Global Research